Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy.

Su YC, Guo X, Qi X.

Biochim Biophys Acta. 2015 Jan;1852(1):12-21. doi: 10.1016/j.bbadis.2014.11.009. Epub 2014 Nov 15.

2.

Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Liu M, Bender SA, Cuny GD, Sherman W, Glicksman M, Ray SS.

Biochemistry. 2013 Mar 12;52(10):1725-36. doi: 10.1021/bi3012077. Epub 2013 Mar 1.

3.

GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.

Chen J, Liou A, Zhang L, Weng Z, Gao Y, Cao G, Zigmond MJ, Chen J.

Front Biosci (Elite Ed). 2012 Jun 1;4:2365-77.

4.

Models for LRRK2-Linked Parkinsonism.

Li T, Yang D, Sushchky S, Liu Z, Smith WW.

Parkinsons Dis. 2011;2011:942412. doi: 10.4061/2011/942412. Epub 2011 Apr 7.

5.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

6.

The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.

Covy JP, Giasson BI.

J Neurochem. 2010 Oct;115(1):36-46. doi: 10.1111/j.1471-4159.2010.06894.x. Epub 2010 Aug 19.

7.

Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.

Covy JP, Giasson BI.

Biochem Biophys Res Commun. 2009 Jan 16;378(3):473-7. doi: 10.1016/j.bbrc.2008.11.048. Epub 2008 Nov 21. Erratum in: Biochem Biophys Res Commun. 2009 Sep 18;387(2):419-20.

8.

Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations.

Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI.

Mov Disord. 2009 Jan 15;24(1):32-9. doi: 10.1002/mds.22096.

9.

Targets for neuroprotection in Parkinson's disease.

Yacoubian TA, Standaert DG.

Biochim Biophys Acta. 2009 Jul;1792(7):676-87. doi: 10.1016/j.bbadis.2008.09.009. Epub 2008 Oct 1. Review.

10.

Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.

Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA.

J Neurol Neurosurg Psychiatry. 2006 May;77(5):665-7.

11.

Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium.

Paisán-Ruíz C, Evans EW, Jain S, Xiromerisiou G, Gibbs JR, Eerola J, Gourbali V, Hellström O, Duckworth J, Papadimitriou A, Tienari PJ, Hadjigeorgiou GM, Singleton AB.

J Med Genet. 2006 Feb;43(2):e9.

12.

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81. Epub 2005 Dec 13.

Supplemental Content

Support Center